- Pfizer's (NYSE:PFE) blockbuster menopause drug Premarin may increase the risk of blood clots compared to estradiol, new research suggests.
- Although the results will need to be replicated in order to draw any definitive conclusions, it could be that oral estrogens aren't created equal in terms of safety, the study's lead author tells Bloomberg.